Comprehensive CQA Analysis for AAV Drug Production by Multiple Workflows on a single CE platform

As gene therapy expands into mainstream clinical use, AAV drug production faces mounting pressure for scalability, reproducibility, and regulatory precision. Central to success is comprehensive CQA analysis—the detailed characterization of Critical Quality Attributes across the entire AAV product lifecycle.

Modern capillary electrophoresis (CE) platforms now support multi-dimensional quality analysis for AAV vectors from upstream plasmid DNA to downstream capsid characterization. This technical breakthrough enables therapeutic developers to streamline workflows, enhance compliance, and minimize batch-to-batch variability within a single, scalable system.

What Is Comprehensive CQA Analysis and Why Does It Matter?

Understanding Critical Quality Attributes (CQAs)

CQAs are product characteristics that must be controlled within limits to ensure safety, efficacy, and stability. For AAV-based drugs, CQAs span multiple domains, including:

• Capsid identity and purity
• Empty/full capsid ratio
• Residual host cell proteins and DNA
• Genomic DNA integrity
• Aggregates and impurities

Each of these impacts the potency, safety, and long-term performance of the therapy.

Traditional Challenges in CQA Workflows

Historically, CQA analysis required a patchwork of platforms—HPLC for DNA purity, ELISA for impurities, and qPCR for residuals. This fragmented approach:

• Increased turnaround times
• Added cost and labor
• Introduced a higher risk of variability

Modern CE platforms consolidate all these steps, making comprehensive CQA analysis accessible on a single, harmonized system.

Streamlining AAV Drug Production With CE-Based Workflows

From Plasmid to Capsid: Multi-Stage Quality Control

The CE-based solution supports AAV drug production at every stage:

• Plasmid DNA analysis using high-resolution CE and the DNA 20 kb kit ensures vector genome integrity before transfection.
• RNA integrity is evaluated with the RNA 9000 Purity & Integrity Kit.
• Protein composition and capsid assembly are verified using CE-SDS analysis.
• Full vs. empty capsid quantification is done with a novel, high-resolution CE method offering sharper peak separation and better reproducibility than traditional methods.

Each of these methods can be run on a single platform, reducing tech transfer hurdles and accelerating scale-up.

Benefits of an Integrated CE Approach

• Eliminates the need for multiple instruments
• Reduces analyst training burden
• Ensures regulatory compliance with clear, quantitative data
• Accelerates method development through flexible assay design

References

• FDA: Approved Gene Therapies
• PubMed: AAV Delivery Success Factors
• Nature Biotechnology: AAV Manufacturing Challenges
• SCiEX: AAV Method Optimization
• SCiEX DNA 20 kb Kit Guide

Ready to simplify your AAV analytics?

Download the full technical guide to explore how one CE platform supports multiple CQA assays, streamlining your AAV drug production process while reducing time and cost.